N-acetylcysteine (NAC) in the treatment of Obsessive-Compulsive Disorder (OCD)

N-acetylcysteine (NAC) in the treatment of Obsessive-Compulsive Disorder (OCD)

CONDITION

Mental Health

GENDER

Both males and females

AGE GROUP

18 years to 75 years

TRIAL STATUS

Recruiting

A 24-week, double blind placebo study investigating the effects of the amino acid ‘N-acetylcysteine’ (NAC) in Obsessive-Compulsive Disorder (OCD). This study will determine if NAC is an effective treatment for individuals with OCD.

This NHMRC funded study is currently enrolling participants at 3 trial sites – The University of Melbourne, University of Queensland and Western Sydney University. We aim to recruit 200 participants – the largest NAC trial for OCD to date.

Eligible participants will be randomised to receive NAC (2,000mg – 4,000mg per day) or placebo capsules alongside their treatment as usual for a period of 6 months. Monthly assessments with a research assistant at their designated trial site (approx. 60-90 mins) will determine if any improvements have occurred in OCD symptoms, as well as depression, anxiety and quality of life.

Visit ocd-research.com for further details.

 

CONTACT DETAILS

Phone Number: 03) 9487 4659
Email: georgina.oliver@unimelb.edu.au
Location: 2 Salisbury St, Richmond, Victoria, Australia

Butterfield St, Herston, Queensland, Australia

Westmead New South Wales, Australia

CONTACT SITE

Approved By: TMC Research Ethics Committee              

Clinical Trial Registry Link: